Table 3.
Primary Outcomes of the Patients Received Obinutuzumab Therapy
| Primary Outcomes | Overall Cohort (N = 18) |
|---|---|
| Total follow-up period, mo, median (IQR) | 13.6 (11.9-14.9) |
| Total obinutuzumab dose during follow-up, g, mean ± SD | 2.1 ± 0.8 |
| Time to first remission, mo, median (IQR) | 2.7 (1.0-6.1) |
| First relapse-free survival time during follow-up, mo, median (IQR) | 9.8 (2.6-11.2) |
| Remission rate during follow-up, n (%)a | 17 (94.4%) |
| Partial remission rate during follow-up, n (%) | 12 (66.7%) |
| Complete remission rate during follow-up, n (%) | 5 (27.8%) |
| Remission rate in 6 mo, n (%) | 13 (72.2%) |
| Remission rate in 12 mo, n (%) | 16 (88.9%) |
Abbreviations: IQR, interquartile range; SD, standard deviation.
a
Includes those who achieved either partial remission or complete remission during the follow-up period.